A Phase 3 interventional study of Placebo and CP690,550 in Ulcerative Colitis, sponsored by Pfizer. Completed at 275 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-18.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.
Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18+
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18–65
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2008; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 593 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 107 across the 14 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 6th registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
3 of the studies testing tofacitinib in Colitis, Ulcerative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT07297069Asian Institute of Gastroenterology, IndiaCombination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial | 2027-05-31 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing tofacitinib in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: CP690,550
Drug: CP-690,550
Placebo 10 mg orally (PO) twice a day (BID)
CP-690,550 5 mg orally (PO) twice a day (BID)
CP-690,550 10 mg orally (PO) twice a day (BID)
Percentage of Participants In Remission at Week 52
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and physician global assessment (PGA), each subscore graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12 where higher score indicating higher disease severity.
Time frame: Week 52
Percentage of Participants With Mucosal Healing at Week 52
Mucosal healing in participants was defined by mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Time frame: Week 52
Percentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission (among participants with remission at baseline) were reported in this outcome measure.
Time frame: Week 24, 52
Percentage of Participants in Remission at Week 24
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Week 24
Percentage of Participants in Sustained Remission
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants With Mucosal Healing at Week 24
Mucosal healing in participants was defined by a mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time frame: Week 24
Percentage of Participants With Sustained Mucosal Healing
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants With Mucosal Healing at Week 24 and 52, Among Participants With Mucosal Healing at Baseline
Mucosal healing in participants was defined as achieving mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants With Clinical Response at Week 24 and 52
Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with clinical response at Week 24 and 52 have been reported in this outcome measure.
Time frame: Week 24, 52
Percentage of Participants With Sustained Clinical Response
Sustained clinical response in participants was defined as showing clinical response at both Week 24 and Week 52. Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained clinical response are reported in this outcome measure.
Time frame: Week 24, 52
Percentage of Participants in Clinical Remission at Week 24 and 52
Clinical remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Sustained Clinical Remission
Sustained clinical remission in participants was defined as being in clinical remission at both Week 24 and Week 52. Clinical remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Deep Remission at Week 24 and 52
Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Sustained Deep Remission
Sustained deep remission was defined by being in deep remission at both Week 24 and Week 52. Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Symptomatic Remission at Week 24 and 52
Symptomatic remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub-scores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Sustained Symptomatic Remission
Sustained symptomatic remission in participants was defined as being in symptomatic remission at both Week 24 and Week 52. Symptomatic remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Endoscopic Remission at Week 24 and 52
Endoscopic remission in participants was defined as a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Sustained Endoscopic Remission
Sustained endoscopic remission in participants was defined as being in endoscopic remission at both Week 24 and Week 52. Endoscopic remission was defined by a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Time frame: Week 24, 52
Total Mayo Score at Baseline, Week 24 and 52
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time frame: Baseline, Week 24, 52
Change From Baseline in Total Mayo Score at Week 24 and 52
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Change from baseline in total mayo score at Week 24 and 52 was reported.
Time frame: Baseline, Week 24, 52
Percentage of Participants in Remission, Among Participants With Remission at Baseline
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Sustained Remission, Among Participants With Remission at Baseline
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Time frame: Week 24, 52
Percentage of Participants in Steroid-free Remission, Among Participants in Remission at Baseline
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants in steroid-free remission were reported in this outcome measure.
Time frame: Week 24, 52
Percentage of Participants in Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with steroid-free remission were reported in this outcome measure.
Time frame: Week 24, 52
Percentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission were reported in this outcome measure.
Time frame: Week 24, 52
| Milestone | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Started | 198 | 197 | 198 |
| Treated | 198 | 196 | 198 |
| Completed | 111 | 126 | 53 |
| Not completed | 87 | 71 | 145 |
| Withdrew: Adverse event | 5 | 9 | 7 |
| Withdrew: Lack of efficacy | 70 | 53 | 132 |
| Withdrew: Lost to follow-up | 3 | 2 | 1 |
| Withdrew: Pregnancy | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 5 |
| Withdrew: Other | 2 | 1 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 |
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and physician global assessment (PGA), each subscore graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12 where higher score indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants In Remission at Week 52 | 34.3 | 40.6 | 11.1 |
Mucosal healing in participants was defined by mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 52 | 37.4 | 45.7 | 13.1 |
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission (among participants with remission at baseline) were reported in this outcome measure.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline | 35.4 | 47.3 | 5.1 |
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Remission at Week 24 | 33.8 | 35.5 | 11.1 |
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Sustained Remission | 22.2 | 25.4 | 5.1 |
Mucosal healing in participants was defined by a mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 24 | 43.9 | 46.2 | 17.2 |
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Sustained Mucosal Healing | 27.8 | 33.0 | 6.6 |
Mucosal healing in participants was defined as achieving mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 52.4 | 66.3 | 21.8 |
| Week 52 | 41.9 | 55.1 | 11.9 |
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline | 33.3 | 49.4 | 8.9 |
Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with clinical response at Week 24 and 52 have been reported in this outcome measure.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 63.6 | 70.6 | 33.3 |
| Week 52 | 51.5 | 61.9 | 20.2 |
Sustained clinical response in participants was defined as showing clinical response at both Week 24 and Week 52. Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained clinical response are reported in this outcome measure.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Sustained Clinical Response | 49.0 | 59.4 | 19.2 |
Clinical remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 34.3 | 35.5 | 11.1 |
| Week 52 | 34.3 | 41.1 | 11.1 |
Sustained clinical remission in participants was defined as being in clinical remission at both Week 24 and Week 52. Clinical remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Sustained Clinical Remission | 22.2 | 25.9 | 5.1 |
Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 14.1 | 10.7 | 4.0 |
| Week 52 | 14.6 | 15.2 | 4.0 |
Sustained deep remission was defined by being in deep remission at both Week 24 and Week 52. Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Sustained Deep Remission | 6.1 | 3.6 | 0.5 |
Symptomatic remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub-scores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 23.7 | 21.8 | 6.6 |
| Week 52 | 22.7 | 26.9 | 7.1 |
Sustained symptomatic remission in participants was defined as being in symptomatic remission at both Week 24 and Week 52. Symptomatic remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Sustained Symptomatic Remission | 13.6 | 15.7 | 2.5 |
Endoscopic remission in participants was defined as a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 16.2 | 12.2 | 4.0 |
| Week 52 | 14.6 | 16.8 | 4.0 |
Sustained endoscopic remission in participants was defined as being in endoscopic remission at both Week 24 and Week 52. Endoscopic remission was defined by a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Sustained Endoscopic Remission | 6.1 | 5.1 | 0.5 |
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
| units on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Baseline (n = 198, 197, 198) | 3.3 ± 1.8 | 3.4 ± 1.8 | 3.3 ± 1.8 |
| Week 24 (n = 179, 186, 181) | 4.1 ± 3.4 | 4.0 ± 3.3 | 6.7 ± 3.5 |
| Week 52 (n = 129, 137, 68) | 3.2 ± 3.1 | 2.6 ± 2.7 | 4.6 ± 3.2 |
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Change from baseline in total mayo score at Week 24 and 52 was reported.
| units on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Change at Week 24 (n = 179, 186, 181) | 0.3 ± 0.3 | 0.0 ± 0.3 | 2.9 ± 0.3 |
| Change at Week 52 (n = 129, 137, 68) | 0.4 ± 0.3 | -0.4 ± 0.3 | 2.9 ± 0.4 |
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 55.4 | 63.6 | 15.3 |
| Week 52 | 46.2 | 56.4 | 10.2 |
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Sustained Remission, Among Participants With Remission at Baseline | 36.9 | 47.3 | 5.1 |
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants in steroid-free remission were reported in this outcome measure.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 53.8 | 63.6 | 15.3 |
| Week 52 | 44.6 | 56.4 | 10.2 |
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with steroid-free remission were reported in this outcome measure.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Week 24 | 23.8 | 24.1 | 10.9 |
| Week 52 | 27.7 | 27.6 | 10.9 |
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission were reported in this outcome measure.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline | 12.9 | 16.1 | 5.0 |
Collected over Baseline up to Week 57. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 5 mg BID | — | 10/198 (5.1%) | 87/198 (43.9%) |
| Tofacitinib 10 mg BID | — | 11/196 (5.6%) | 107/196 (54.6%) |
| Placebo | — | 13/198 (6.6%) | 108/198 (54.5%) |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 2/198 | 1/196 | 8/198 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/95 | 0/86 | 1/82 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/95 | 0/86 | 0/82 |
| Abdominal painGastrointestinal disorders | 0/198 | 1/196 | 0/198 |
| DiarrhoeaGastrointestinal disorders | 0/198 | 1/196 | 0/198 |
| Cholecystitis acuteHepatobiliary disorders | 0/198 | 1/196 | 0/198 |
| Bacterial diarrhoeaInfections and infestations | 0/198 | 1/196 | 0/198 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/198 | 1/196 | 0/198 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/198 | 1/196 | 0/198 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/198 | 1/196 | 0/198 |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 35/198 | 29/196 | 64/198 |
| NasopharyngitisInfections and infestations | 19/198 | 27/196 | 11/198 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/198 | 17/196 | 19/198 |
| HeadacheNervous system disorders | 17/198 | 6/196 | 12/198 |
| Blood creatine phosphokinase increasedInvestigations | 6/198 | 13/196 | 4/198 |
| Upper respiratory tract infectionInfections and infestations | 13/198 | 12/196 | 7/198 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 4/198 | 11/196 | 2/198 |
| RashSkin and subcutaneous tissue disorders | 6/198 | 11/196 | 8/198 |
| Abdominal painGastrointestinal disorders | 5/198 | 7/196 | 11/198 |
| FatigueGeneral disorders | 8/198 | 4/196 | 11/198 |
Full analysis set (FAS) included all randomized participants.
| Age, Continuous(years) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 41.9 ± 13.7 | 42.9 ± 14.4 | 43.4 ± 14 | 42.7 ± 14 |
| Sex: Female, Male(Participants) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo | Total |
|---|---|---|---|---|
| Female | 95 | 87 | 82 | 264 |
| Male | 103 | 110 | 116 | 329 |
Showing the first 100 of 275 sites across 31 countries. Choose a country and city above to see the rest.
Ran from Jul 2012 to primary completion in May 2016, 46 months.
Results were first posted in May 2017, 11 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 46 months is close to that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib